Harvard Management Company’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Harvard Management Company’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-462,418	Closed	-$1.4M	–	31
2023 Q2	$1.4M	Sell	462,418 -35,583	-7%	-$137K	0.14%	23
2023 Q1	$3.11M	Hold	498,001	–	–	0.33%	26
2022 Q4	$3.04M	Hold	498,001	–	–	0.38%	28
2022 Q3	$5.95M	Hold	498,001	–	–	0.74%	21
2022 Q2	$6.28M	Hold	498,001	–	–	0.73%	22
2022 Q1	$5.61M	Hold	498,001	–	–	0.57%	27
2021 Q4	$8.82M	Hold	498,001	–	–	0.83%	22
2021 Q3	$11.5M	Hold	498,001	–	–	0.67%	22
2021 Q2	$11.6M	Hold	498,001	–	–	0.67%	22
2021 Q1	$15.5M	Hold	498,001	–	–	0.87%	20
2020 Q4	$19.8M	Buy	+498,001	New	+$20M	1.07%	13

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Harvard Management Company's KNTE Position: Q3 2023 in Review

Harvard Management Company sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 462,418 shares — an estimated $1.4M sold.

Harvard Management Company first reported a position in KNTE in Q4 2020 and held it in 11 quarters. The position peaked at $19.8M in Q4 2020. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

Harvard Management Company reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Harvard Management Company sold 462,418 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $1.4M.
Harvard Management Company first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Harvard Management Company's Kinnate Biopharma Inc. Common Stock position peaked at $19.8M in Q4 2020.
58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on Harvard Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.